Goldman Sachs has contributed a $20m extension to a Tasly Pharmaceuticals-backed round that achieved a first close at $35m in September.

China-based biotechnology company Ascletis secured a $20m extension to a series B round backed by drug developer Tasly Pharmaceuticals, from investment bank Goldman Sachs yesterday, to close the round at $55m.

Tasly co-led the round’s $35m first tranche in September 2015 with venture capital fund C-Bridge Capital and Pavilion Capital, a subsidiary of Singaporean state-owned fund Temasek.

Founded in 2011, Ascletis is developing treatments for infectious conditions such as HIV and cancer. The company has licensed one drug candidate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?